Compare Adaptive Biotechnologies Corp (ADPT) vs Burlington Stores Inc (BURL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Burlington Stores Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Burlington Stores Inc trades at $315.52 (market cap $19.90B). The key difference: Burlington Stores Inc is far larger — about 6× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Burlington Stores Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | BURL | |
|---|---|---|
Market Cap | $3.33B | $19.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $347.82 |
52-Week Low | $10.24 | $242.43 |
Enterprise Value | $3.19B | $25.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Burlington Stores (BURL) trades at $312.36, showing modest daily decline of -0.26% but maintaining strong fundamental performance with consistent earnings beats. The stock exhibits bearish technical signals despite positive analyst sentiment, with 94% buy ratings and a $364.40 consensus price target. Recent Q1 2026 results exceeded expectations with $2.01 EPS versus $1.80 expected, marking the 14th consecutive quarter of double-digit earnings growth.
BURL presents a compelling growth story with expanding margins and store expansion plans, though technical indicators suggest near-term caution. The stock's premium valuation (P/E 32.14) reflects growth expectations, while competitive pressures and consumer spending sensitivity remain key risks. Upside potential exists toward analyst targets if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Burlington Stores Inc
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →
